"Top Analyst-Backed Stocks Poised for Monumental Growth in 2024"
Three Motley Fool contributors have highlighted potential stock winners for 2024: CRISPR Therapeutics, with its newly approved gene-editing therapy Casgevy; Madrigal Pharmaceuticals, which is awaiting FDA approval for its NASH treatment resmetirom; and Verona Pharma, with its COPD treatment ensifentrine under FDA review. CRISPR Therapeutics is launching its high-priced gene therapy, Madrigal is in a strong financial position for a potential drug launch, and Verona Pharma's drug could significantly impact the COPD market if approved. These stocks are considered to have significant upside potential by the contributors, despite the inherent risks of the biotech sector.